OptiNose, Inc. (OPTN): Price and Financial Metrics

OptiNose, Inc. (OPTN): $1.22

0.02 (-1.61%)

POWR Rating

Component Grades








Add OPTN to Watchlist
Sign Up

OPTN Price/Volume Stats

Current price $1.22 52-week high $2.10
Prev. close $1.24 52-week low $0.90
Day low $1.16 Volume 796,700
Day high $1.25 Avg. volume 538,569
50-day MA $1.52 Dividend yield N/A
200-day MA $1.30 Market Cap 137.44M

OPTN Stock Price Chart Interactive Chart >

OptiNose, Inc. (OPTN) Company Bio

OptiNose, Inc. focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. The company was founded in 2010 and is based in Yardley, Pennsylvania.

OPTN Latest News Stream

Event/Time News Detail
Loading, please wait...

OPTN Latest Social Stream

Loading social stream, please wait...

View Full OPTN Social Stream

Latest OPTN News From Around the Web

Below are the latest news stories about OPTINOSE INC that investors may wish to consider to help them evaluate OPTN as an investment opportunity.

Optinose Announces 3-Month Extension of FDA Review Period for the Supplemental New Drug Application for XHANCE

The application is based on phase 3 results from the ReOpen clinical trial program showing XHANCE significantly reduced symptoms and sinus opacification in participants with chronic rhinosinusitis If approved, XHANCE is expected to be the first and only drug indicated for the treatment of chronic rhinosinusitis, a diagnosis which is assigned at approximately 10 million patient visits annually YARDLEY, Pa., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused

Yahoo | December 6, 2023

Optinose to Present at the 35th Annual Piper Sandler Healthcare Conference

YARDLEY, Pa., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced that members of its management team will present a company overview and business update at the 35th Annual Piper Sandler Healthcare Conference on November 29, 2023, at 3:30 p.m. ET. To listen to a webcast of the presentation live, please visit the Investors page of the Optinose website. A replay of the

Yahoo | November 22, 2023

Owning 47% shares,institutional owners seem interested in OptiNose, Inc. (NASDAQ:OPTN),

Key Insights Institutions' substantial holdings in OptiNose implies that they have significant influence over the...

Yahoo | November 17, 2023

OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript

OptiNose, Inc. (NASDAQ:OPTN) Q3 2023 Earnings Call Transcript November 9, 2023 OptiNose, Inc. beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good day and thank you for standing by. Welcome to OptiNose Third Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers’ presentation, […]

Yahoo | November 11, 2023

OptiNose Inc (OPTN) Reports Q3 2023 Financial Results with Improved Operating Efficiency

Key Financial Highlights and Operational Updates

Yahoo | November 9, 2023

Read More 'OPTN' Stories Here

OPTN Price Returns

1-mo -35.11%
3-mo -3.94%
6-mo 10.91%
1-year -35.79%
3-year -65.24%
5-year -88.04%
YTD -5.43%
2023 -30.27%
2022 14.20%
2021 -60.87%
2020 -55.10%
2019 48.71%

Continue Researching OPTN

Here are a few links from around the web to help you further your research on OptiNose Inc's stock as an investment opportunity:

OptiNose Inc (OPTN) Stock Price | Nasdaq
OptiNose Inc (OPTN) Stock Quote, History and News - Yahoo Finance
OptiNose Inc (OPTN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!